- Home
- RETO vs HOOK Comparison
RETO vs HOOK Comparison
Compare RETO & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RETO
- HOOK
- Stock Information
- Founded
- RETO 1999
- HOOK 2011
- Country
- RETO China
- HOOK United States
- Employees
- RETO N/A
- HOOK N/A
- Industry
- RETO Multi-Sector Companies
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- RETO Consumer Discretionary
- HOOK Health Care
- Exchange
- RETO Nasdaq
- HOOK Nasdaq
- Market Cap
- RETO 10.0M
- HOOK 9.3M
- IPO Year
- RETO 2017
- HOOK 2019
- Fundamental
- Price
- RETO $3.62
- HOOK $1.44
- Analyst Decision
- RETO
- HOOK Buy
- Analyst Count
- RETO 0
- HOOK 4
- Target Price
- RETO N/A
- HOOK $10.67
- AVG Volume (30 Days)
- RETO 384.7K
- HOOK 148.4K
- Earning Date
- RETO 06-26-2025
- HOOK 05-27-2025
- Dividend Yield
- RETO N/A
- HOOK N/A
- EPS Growth
- RETO N/A
- HOOK N/A
- EPS
- RETO N/A
- HOOK N/A
- Revenue
- RETO $1,828,976.00
- HOOK $43,946,000.00
- Revenue This Year
- RETO N/A
- HOOK N/A
- Revenue Next Year
- RETO N/A
- HOOK N/A
- P/E Ratio
- RETO N/A
- HOOK N/A
- Revenue Growth
- RETO N/A
- HOOK 118.32
- 52 Week Low
- RETO $0.33
- HOOK $0.72
- 52 Week High
- RETO $7.10
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- RETO 53.52
- HOOK 61.47
- Support Level
- RETO $3.02
- HOOK $1.22
- Resistance Level
- RETO $3.75
- HOOK $1.47
- Average True Range (ATR)
- RETO 0.36
- HOOK 0.19
- MACD
- RETO 0.01
- HOOK 0.03
- Stochastic Oscillator
- RETO 55.56
- HOOK 69.36
About RETO ReTo Eco-Solutions Inc.
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly-ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation and construction of urban ecological environments for capturing, controlling and re-using rainwater. It operates through four segments namely Machinery and Equipment sales, Construction materials sales, Municipal Construction Projects, and Technology Consulting and other services. The company earns its revenue from Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.